Journal of Gastrointestinal Surgery

, Volume 16, Issue 8, pp 1516–1523

Role of Operative Therapy in Non-cirrhotic Patients with Metastatic Hepatocellular Carcinoma

  • Victor Zaydfudim
  • Rory L. Smoot
  • Clancy J. Clark
  • Michael L. Kendrick
  • Florencia G. Que
  • Michael B. Farnell
  • David M. Nagorney
Original Article

Abstract

Introduction

We investigated the role of operative therapy in non-cirrhotic patients who developed metastatic hepatocellular carcinoma (HCC).

Methods

This retrospective cohort study included consecutive non-cirrhotic patients with metastatic HCC after a prior hepatectomy treated between 1990 and 2009. Patients were stratified by operative therapy (resection, ablation, transcatheter therapy). Kaplan–Meier analyses with log-rank comparisons tested effects of operative therapy on overall survival (OS) and progression-free survival (PFS).

Results

Of 195 non-cirrhotic patients treated for HCC during the study period, 98 [median age 65, interquartile range (IQR) 53–71; 55 % male] subsequently developed metastatic HCC (55 intrahepatic only). Median time to development of metastases after the index operation was 10 months (IQR 5–20 months); median number of metastases was 3 (IQR 2–7). Half of these patients (n = 50) underwent operative treatment of metastases; 20 (40 %) underwent metastasectomy, 18 (36 %) ablation, and 12 (24 %) transcatheter therapy. Operative therapy was associated with improved OS (p < 0.001). Resection or ablation was associated with improved PFS and OS compared to transcatheter therapy (all p ≤ 0.006). Nine patients (seven resection, two ablation) are disease free at a median of 50 months (IQR 24–80 months) posttreatment.

Conclusions

Resection and ablation are associated with an improved PFS and long-term OS and should be considered in select patients with metastatic HCC.

Keywords

Hepatocellular carcinoma Recurrence Metastasis HCC Metastasectomy Sorafenib Outcome Resection Ablation 

References

  1. 1.
    Benson AB, 3rd, Abrams TA, Ben-Josef E, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 2009;7:350–91.PubMedGoogle Scholar
  2. 2.
    Jung SM, Jang JW, You CR, et al. Role of intrahepatic tumor control in the prognosis of patients with hepatocellular carcinoma and extrahepatic metastases. J Gastroenterol Hepatol 2012; 27:684–89.PubMedCrossRefGoogle Scholar
  3. 3.
    Chua TC, Morris DL. Exploring the role of resection of extrahepatic metastases from hepatocellular carcinoma. Surg Oncol 2011 (published ahead of print date; doi:10.1016/j.suronc.2011.01.005).
  4. 4.
    Leong TY, Leong AS. Epidemiology and carcinogenesis of hepatocellular carcinoma. HPB (Oxford) 2005;7:5–15.CrossRefGoogle Scholar
  5. 5.
    Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis 2010;30:3–16.PubMedCrossRefGoogle Scholar
  6. 6.
    Jarnagin W, Chapman WC, Curley S, et al. Surgical treatment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford) 2010;12:302–10.Google Scholar
  7. 7.
    Smoot RL, Nagorney DM, Chandan VS, et al. Resection of hepatocellular carcinoma in patients without cirrhosis. Br J Surg 2011;98:697–703.PubMedCrossRefGoogle Scholar
  8. 8.
    Shrager B, Jibara G, Schwartz M, Roayaie S. Resection of Hepatocellular Carcinoma Without Cirrhosis. Ann Surg 2012 (published ahead of print date; doi:10.1097/SLA.0b013e31823e70a3).
  9. 9.
    Cha C, Fong Y, Jarnagin WR, Blumgart LH, DeMatteo RP. Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg 2003;197:753–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429–42.PubMedCrossRefGoogle Scholar
  11. 11.
    Nowak AK, Chow PK, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer 2004;40:1474–84.PubMedCrossRefGoogle Scholar
  12. 12.
    Samuel M, Chow PK, Chan Shih-Yen E, Machin D, Soo KC. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev 2009:CD001199.Google Scholar
  13. 13.
    Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–90.PubMedCrossRefGoogle Scholar
  14. 14.
    Hirokawa F, Hayashi M, Miyamoto Y, et al. Appropriate treatment strategy for intrahepatic recurrence after curative hepatectomy for hepatocellular carcinoma. J Gastrointest Surg 2011;15:1182–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Kwon JB, Park K, Kim YD, et al. Clinical outcome after pulmonary metastasectomy from primary hepatocellular carcinoma: analysis of prognostic factors. World J Gastroenterol 2008;14:5717–22.PubMedCrossRefGoogle Scholar
  16. 16.
    Yoon YS, Kim HK, Kim J, et al. Long-term survival and prognostic factors after pulmonary metastasectomy in hepatocellular carcinoma. Ann Surg Oncol 2010;17:2795–801.PubMedCrossRefGoogle Scholar
  17. 17.
    Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. Seventh ed. New York: Springer; 2010.Google Scholar
  18. 18.
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–81.Google Scholar
  19. 19.
    Wallenstein S, Zucker CL, Fleiss JL. Some statistical methods useful in circulation research. Circ Res 1980;47:1–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Zhu AX. Systemic treatment of hepatocellular carcinoma: dawn of a new era? Ann Surg Oncol 2010;17:1247–56.PubMedCrossRefGoogle Scholar
  21. 21.
    Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008;48:1312–27.PubMedCrossRefGoogle Scholar
  22. 22.
    Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 2010;61:317–28.PubMedCrossRefGoogle Scholar
  23. 23.
    Sieghart W, Pinter M, Reisegger M, et al. Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study. Eur Radiol 2012 (published ahead of print date; doi:10/1007/s00330-011-2368-z).
  24. 24.
    Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 1999;229:216–22.PubMedCrossRefGoogle Scholar
  25. 25.
    Farges O, Regimbeau JM, Belghiti J. Aggressive management of recurrence following surgical resection of hepatocellular carcinoma. Hepatogastroenterology 1998;45 Suppl 3:1275–80.PubMedGoogle Scholar
  26. 26.
    Poon RT, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000;232:10–24.CrossRefGoogle Scholar
  27. 27.
    Ho CM, Lee PH, Shau WY, Ho MC, Wu YM, Hu RH. Survival in patients with recurrent hepatocellular carcinoma after primary hepatectomy: Comparative effectiveness of treatment modalities. Surgery 2012;151:700–09.PubMedCrossRefGoogle Scholar
  28. 28.
    Sakamoto Y, Kubota K, Mori M, et al. Surgical management for adrenal gland metastasis of hepatocellular carcinoma. Hepatogastroenterology 1999;46:1036–41.PubMedGoogle Scholar
  29. 29.
    Nakayama H, Takayama T, Makuuchi M, et al. Resection of peritoneal metastases from hepatocellular carcinoma. Hepatogastroenterology 1999;46:1049–52.PubMedGoogle Scholar
  30. 30.
    Gordon-Weeks AN, Snaith A, Petrinic T, Friend PJ, Burls A, Silva MA. Systematic review of outcome of downstaging hepatocellular cancer before liver transplantation in patients outside the Milan criteria. Br J Surg 2011;98:1201–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Davis E, Wiesner R, Valdecasas J, Kita Y, Rossi M, Schwartz M. Treatment of recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl 2011;17 Suppl 2:S162–6.PubMedCrossRefGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2012

Authors and Affiliations

  • Victor Zaydfudim
    • 1
  • Rory L. Smoot
    • 1
  • Clancy J. Clark
    • 1
  • Michael L. Kendrick
    • 1
  • Florencia G. Que
    • 1
  • Michael B. Farnell
    • 1
  • David M. Nagorney
    • 1
  1. 1.Division of Gastroenterologic and General SurgeryMayo ClinicRochesterUSA

Personalised recommendations